Insulin dose–response effects on memory and plasma amyloid precursor protein in Alzheimer’s disease: interactions with apolipoprotein E genotype

• Published in: Psychoneuroendocrinology 2003-08, Vol.28 (6), p.809-822
• Main Authors: Craft, Suzanne, Asthana, Sanjay, Cook, David G., Baker, Laura D., Cherrier, Monique, Purganan, Kristina, Wait, Colby, Petrova, Andreana, Latendresse, Shawn, Watson, G.Stennis, Newcomer, John W., Schellenberg, Gerard D., Krohn, Aaron J.
• Format: Article
• Language: English
• Subjects: Aged; Alzheimer Disease - genetics; Alzheimer Disease - physiopathology; Amyloid beta-protein precursor; Amyloid beta-Protein Precursor - blood; Amyloid beta-Protein Precursor - drug effects; Analysis of Variance; Apolipoprotein E4; Apolipoproteins e; Apolipoproteins E - genetics; Biological and medical sciences; Blood Glucose - metabolism; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; Diabetes; Dose-Response Relationship, Drug; Energy metabolism; Female; Homozygote; Humans; Insulin - administration & dosage; Insulin - blood; Insulin resistance; Insulin Resistance - physiology; Male; Medical sciences; Mental Recall - drug effects; Mental Recall - physiology; MESH terms; Neurology
• ISSN: 0306-4530; 1873-3360
• DOI: 10.1016/S0306-4530(02)00087-2

In previous studies, adults with Alzheimer’s disease (AD) showed memory enhancement when plasma insulin levels were raised to 85 μU/ml, whereas normal adults’ memory was unchanged. Degree of memory enhancement was also related to apolipoprotein E (apoE) genotype status for AD patients. Response differences between normal and AD groups could reflect dose–response differences for insulin. To examine this question, 22 adults with AD and 15 normal adults received five doses of insulin on separate days in counterbalanced order, resulting in five plasma insulin levels (10, 25, 35, 85 and 135 μU/ml), while plasma glucose levels of ~100 mg/dl were maintained. Cognitive performance and plasma APP levels were measured after 120 min of infusion. Relative to baseline, AD patients who were not apoE-ε4 homozygotes had improved memory at higher insulin levels of 35 and 85 μU/ml, whereas normal adults and AD patients who were ε4 homozygotes showed improved memory at insulin levels of 25 μU/ml. Normal adults’ memory was also improved at insulin levels of 85 μU/ml. Plasma APP was lowered for adults with AD without the ε4 allele at higher levels (85 μU/ml) than for normal adults and ε4 homozygotes, who showed decreased APP at the 35 μU/ml level. AD patients with a single ε4 allele showed a different pattern of insulin effects on APP than did other subjects. In general, few effects of insulin were seen at the highest dose for any subject group. These results support a role for insulin in normal memory and APP modulation that follows a curvilinear response pattern, and suggest that AD patients who are not ε4 homozygotes have reduced sensitivity to insulin that may interfere with such modulation.